The stock of Ascendis Pharma A/S jumped 11% early Monday, after the biotech said the U.S. Food and Drug Administration has approved its Yorvipath as the first and only treatment for a rare endocrine disease.
The number of Americans who applied for unemployment benefits in the week before the Thanksgiving holiday dipped to a seven-month low in a sign of strength for a steadily expanding U.S. economy.